The mortality rate of portal hypertension complicated with variceal bleeding in decompensated liver cirrhosis patients decreased dramatically in recent three decades,mainly benefited from the“forward blood flow”hypothesis proposed in the 1980s and splanchnic vascular tone theory to explain the mechanism of portal hypertension in advanced liver cirrhosis,thereby introducing clinically three types of drugs,namely,somatostatin and its derivatives,terlipressin,and nonselective beta blockers. The abovementioned drugs together with endoscopic variceal ligation, sclerotherapy and histoacryl injection have made a milestone contribution to the dramatic decreasing of mortality rate in liver cirrhosis patients with portal hypertension and bleeding. Recent advances in knowledge on the molecular mechanisms of increase of hepatic portal blood inflow,hepatic sinusoidal endothelium dysfunction and neovascularization form the basis of current emerging therapies for portal hypertension. We can expect that most likely this will result in more effective treatment and prevention for portal hypertension in liver cirrhosis patients.

Acromegaly is an endocrine and metabolic disease with insidious onset. Delays in its diagnosis and treatment significantly increase the incidence of complications. Early detection, diagnosis, and treatment are extremely important for the prognosis of patients with acromegaly. Based on a large quantity of evidence in recent years, Chinese Expert Consensus on the Diagnosis and Treatment of Acromegaly(2020) has standardized the diagnosis and the treatment strategies of acromegaly. In the non-surgical treatment section, according to the categories of drugs used to treat acromegaly, the indications, selection, administration, dosage and precautions of pharmaceutical treatment have been clarified with specific recommendations. It is hoped that the new consensus can further guide and standardize the clinical management of acromegaly.

Child ; Child Nutrition Disorders ; Child Nutrition Sciences ; Humans ; Malnutrition ; Nutritional Status

Child ; Humans ; Rickets ; pathology

ObjectiveTo study the effect of salmon calcitonin in treating knee osteoarthritis.MethodsFortyeight cases of knee osteoarthritis were randomly divided into four groups,twelve cases each group.A group:acetaminophen+glucosamine hydrochloride,B group:meloxicam+glucosamine hydrochloride,C group:salmon calcitonin + glucosamine hydrochloride,D group:salmon calcitonin.Acetaminophen and meloxicam can stop as pain symptoms disappeared.Other drugs were treated for 12 weeks.A follow up was carried out to compare visual analogue score and 12-item short form health survey.ResultsTwelve weeks later,A,B,C,D four groups' visual analogue score decreased from before treatment 5.6±1.2,5.5±1.2,5.4±1.0,5.1±l.2 to 1.9±0.8,1.2±0.7,0.8±0.6,0.9±0.7,12-item short form health survey score from before treatment - 23.4±3.1,- 23.8±3.0,-24.8 ±3.8,-22.4±2.8 to -15.1±4.7、- 14.5±4.7,-9.3±6.2,-10.2±5.3.There was significant difference before and after treatment in every group(P＜ 0.05).The visual analogue scores of B,C and D group outweigh A group's (P＜ 0.05).A and B groups'scores of 12-item short form health survey were lower to C and D groups' ( P ＜ 0.05 ).ConclusionsSalmon calcitonin can relieve pain in treating knee osteoarthritis.

e scale clinical trials.

Anemia, Iron-Deficiency ; prevention & control ; therapy ; Child ; Humans

Allergens ; analysis ; Animals ; Cattle ; Child ; Humans ; Immunoglobulin E ; analysis ; Infant ; Milk Hypersensitivity ; diagnosis ; therapy ; Practice Guidelines as Topic ; Skin Tests

Humans ; Infant ; Rickets ; diagnosis ; pathology ; Risk Factors ; Vitamin D Deficiency ; complications ; diagnosis ; pathology

Adult ; Arsenic Poisoning ; Arsenicals ; Humans ; Indium ; Male ; Occupational Exposure ; Young Adult